The US Department of Energy (DOE) said on Thursday that its Argonne National Laboratory is exploring the use of artificial intelligence (AI) and high-performance computing resources for the detailed study of the complex dynamics of the spike protein, one of the key proteins that allows the SARS-CoV-2 virus to infiltrate the human immune system in partnership with several companies.
In conjunction with the study, the DOE's collaborative AI work received the 2020 Gordon Bell Special Prize for High Performance Computing-Based COVID-19 Research at SC20, the International Conference for High Performance Computing, Networking, Storage and Analysis. The team's article "AI-Driven Multiscale Simulations Illuminate Mechanisms of SARS-CoV-2 Spike Dynamics," will appear in International Journal of High Performance Computing Applications 2020.
Comprised of nearly 30 researchers across ten organizations, the DOE team is trying to understand how the spike protein binds to and interacts with the human cell's ACE2-receptor protein and eventually allows SARS-CoV-2 to infect the host. The team developed a machine learning method to summarize large volumes of data.
This success follows the DOE's partnership with NVIDIA, a leader in GPU and AI design and the utilization of top US supercomputers, including Summit at the DOE's Oak Ridge National Laboratory; Theta at Argonne; Frontera/Longhorn at Texas Advanced Computing Center; Comet at San Diego Supercomputing Center; and Lassen at DOE's Lawrence Livermore National Laboratory.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial